Interstitial lung disease in rheumatoid arthritis: An update on diagnosis and management

International Journal of Clinical Rheumatology

Volumn 7, Issue 3, 2012, Pages 297-308

  Malik, Saadia ^a   Saravanan, Vadivelu ^a   Kelly, Clive ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

interstitial lung disease; mortality; rheumatoid arthritis; survival

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; WARFARIN;

BLOOD GAS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG BIOPSY; LUNG EMBOLISM; LUNG EXAMINATION; LUNG FIBROSIS; PATIENT IDENTIFICATION; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84862177690     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.12.24     Document Type: Review

References (80)

1. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly CA. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br. J. Rheumatol. 33, 118-122 (1994).
2. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography and pulmonary function tests. Thorax 56, 622-627 (2001).
3. Bongartz T, Nannini C, Medina-Velasquez YF et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 62, 1583-1591 (2010). A good review of the present relevance of rheumatoid arthritis (RA) and interstitial lung disease (ILD) in the population.
4. Koduri G, Norton S, Young A et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort study. Rheumatology 49, 1483-1489 (2010). Important assessment of the role of RA-ILD in contributing to mortality in RA.
5. Gabbay E, Tarala R, Will R et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 156, 528-535 (1997).
6. Park JH, Kim DS, Park IN et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am. J. Respir. Crit. Care Med. 175, 705-711 (2007).
7. Rajasekaran A, Shovlin D, Saravanan V, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis; comparison with cryptogenic fibrosing alveolitis over five years. J. Rheumatol. 33(7), 1250-1254 (2006).
8. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology 41, 676-679 (2002).
9. Young A, Koduri G, Batley M et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46, 350-357 (2007).
10. Lee HK, Lim DS, Yoo B et al. Histologic pattern and clinical features of rheumatoid arthritis associated interstitial lung disease. Chest 127, 2019-2027 (2005).
11. Hyun-Kyung L, Dong-Soon K, Bin Y et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127(6), 2019-2027 (2005). Important paper distinguishing the different subtypes of ILD seen in RA.
12. Kim EJ, Elicker BM, Maldonado F et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur. Respir. J. 35, 1322-1328 (2010).
13. Sathi N, Urwin T, Desmond S, Dawson J. Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease Rheumatology 50(3), 620 (2011).
14. Alexiou I, Germenis A, Koutroumpas A et al. Anti-cylcic citrullinated peptide (CCP) antibodies and extra articular manifestations in Greek patients with rheumatoid arthritis. Clin. Rheumatol. 27, 511-513 (2008).
15. Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr. Opin Rheumatol. 20(3), 340-346 (2008).
16. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin. Biochem. 41, 1873-2933 (2008).
17. Gizinski AM, Mascolo M, Loucks JL et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin. Rheumatol. 28, 611-613 (2009).
18. Reynisdottir G, Nyren S, Harju A et al. Lung changes detected by high resolution tomography are present in ACPA positive RA patients already at disease onset. Am. Coll. Rheumatol. 63, 2176 (2011).
19. Demoruelle M, Weisman M, Derber L et al. Lung abnormalities in subjects with elevations of rheumatoid arthritis-related autoantibodies without arthritis by examination and imaging suggest the lung is an early and perhaps initiating site of inflammation in rheumatoid arthritis. Am. Coll. Rheumatol. 769 (2011).
20. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 50, 3085-3092 (2004).
21. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA et al. Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles. Ann. Rheum. Dis. 52, 3058-3062 (2005).
22. Weyand CM, Schmidt D, Wagner U et al. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 41, 817-822 (1998).
23. Gochuico BR, Avila NA, Chow CK et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch. Intern. Med. 168, 159-166 (2008).
24. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr. Rheumatol. Rep. 12, 363-369 (2010).
25. Rajasekaran AB, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients. with rheumatoid arthritis; a comparison with cryptogenic fibrosing alveolitis. Rheumatology 40, 1022-1025 (2001).
26. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur. Respir. J. 25(5), 915-927 (2005).
27. Sugiyama Y, Ohmo S, Kano S. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern. Med. 33, 612-614 (1994).
28. Charles PJ, Sweatman MC, Marckwick JR et al. HLA-B40 a marker for susceptibility to lung disease in rheumatoid arthritis. Dis. Markers 9(2), 97-101 (1991).
29. Clarkson R, Bate AS, Grennan DM et al. DQw7 and C4B null allele in rheumatoid arthritis and Feltys syndrome. Ann. Rheum. Dis. 49, 976-979 (1990).
30. Michalski JP, McCombs CC, Scopelatis E et al. Alpha 1 antitrypsin phenotypes in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum. 29, 586-591 (1986).
31. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136, 1397-1405 (2009) A useful comparison of the histological and radiological features of RA-ILD.
32. Flaherty KR, Colby RV, Travis WD et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am. J. Respir. Crit. Care Med. 167, 1410-1415 (2003).
33. Yoo J-W, Song JW, Jang SJ et al. Comparison between cryptogenic organising pneumonia and connective tissue disease related organising pneumonia. Rheumatology 50, 932-938 (2011).
34. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248-1254 (2008).
35. Hassan WU, Keaney NP, Holland CD, Kelly CA. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann. Rheum. Dis. 54, 308-310 (1995).
36. Haykawa H, Sato A, Imokawa S et al. Bronchiolar disease in rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 154, 1531-1536 (1996).
37. Vergnenegre A, Pugnere N, Antonimi NT et al. Airways obstruction and rheumatoid arthritis. Eur. Respir. J. 10, 1072-1078 (1997).
38. Raghu G, Depaso W, Cain K et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double blind randomised placebo controlled clinical trial. Am. Rev. Respir. Dis. 144, 291-296 (1991).
39. Collard HR, Ryu JH, Douglas WW et al. Combined corticosteroids and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 125, 2169-2174 (2004).
40. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655-2666 (2006).
41. Vassallo R, Thomas CF. Advances in treatment of rheumatic interstitial lung disease. Curr. Opin Rheumatol. 16, 186-191 (2004).
42. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353(21), 2229-2242 (2005). First important therapeutic evidence of efficacy for N-acetylcysteine.
43. Hubbard R, Barker B, Fogarty A, Smith C. Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF). Eur. Respir. J. 30, 574 (2007).
44. Kubo H, Nakayama K, Yanai M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128, 1475-1482 (2005).
45. Zamora AC, Wolters PJ, Collard HR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir. Med. 102(1), 150-155 (2008).
46. Swigris J, Olson A, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130, 30-33 (2006).
47. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133, 455-460 (2008).
48. Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as firstline treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45, 1005-1008 (2006).
49. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Lague R, Vilardell-Tarres M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin. Rheumatol. 30, 1393-1398 (2011).
50. Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch. Intern. Med. 168(15), 1718-1719 (2008). First report of effective use of mycophenolate in RA-ILD.
51. Lim SW, Gillis D, Smith W et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern. Med. J. 36, 260-262 (2006).
52. Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673-2677 (2002).
53. Ng KP, Leandro MJ, Edwards, JC et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 65, 942-945 (2006).
54. Sem M, Molberg O, Lund M, Gran J. Rituximab treatment of the anti-synthetase syndrome - a retrospective case series. Rheumatology 48, 968-971 (2009).
55. Efthimiou P, Kukar M, Hersh A. Rituximab and lupus interstitial lung disease: friend or foe? Int. J. Rheumat. Dis. 14, e3-e4 (2011).
56. Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 60, 578-583 (2009).
57. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology 48, 447-448 (2009).
58. McGonagle D, Tan A, Madden J et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47, 552-553 (2008).
59. Lambotte O, Kotb R, Maigne G, Blanc F, Goujard C, Delfraissy J. Efficacy of rituximab in refractory polymyositis. J. Rheumatol. 32, 1369-1370 (2005).
60. Atkins SA, Turesson C, Myers JL et al. Morphologic and quantitative assessment of CD-20 B cell infiltrates in rheumatoid arthritis associated non specific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 54, 635-641 (2006).
61. Matteson EL, Dellaripa PF, Ryu JH, Crowson CS, Hartman TE, Bongartz T. Open-label, pilot study of the safety and clinical effects of Rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Am. Coll. Rheumatol. 63, 2212 (2011).
62. Dass S, Vital EM, Bingham S, Emery P. Rituximab in RA: 5 years of real life clinical experience. Rheumatology 47(Suppl. 2), ii48.161 (2008). Useful review of the safety profile of rituximab in patients with RA-ILD.
63. Dale J, Stirling A, Johnston L, Gordon M-M. Rituximab in rheumatoid arthritis: Defining its role in daily clinical practice. Rheumatology 47(Suppl. 2), ii33.110 (2008).
64. Popa C, Leandro M, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology 46, 626-630 (2007).
65. Leon R, Gonsalvo A, Salas R, Hidalgo N. Rituximab-induced acute pulmonary fibrosis. Mayo Clin. Proc. 79, 945-956 (2004).
66. Wagner SA, Mehta DC, Laber DA. Rituximab-induced interstitial lung disease. Am. J. Hematol. 82, 916-919 (2007). Important review of potential pulmonary complications of rituximab.
67. Liote H, Liote F, Seroussi B et al. Rituximab-induced lung disease: a systematic literature review. Eur. Respir. J. 35, 681-687 (2009).
68. Howes M, Tose J, White C, Kumar N, Heycock C, Kelly C. Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis. Intern. Med. 7, 51-54 (1999).
69. Chikura B, Sathi N, Lane S, Dawson J. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology. 47, 1647-1650 (2008).
70. Sathi N, Chikura B, Kaushik VV, Wiswell R, Dawson JK. How common is methotrexate pneumonitis? A large prospective study investigates. Clin. Rheumatol. 31, 79-83 (2012).
71. Saravanan V, Kelly CA. Drug related pulmonary problems in patients with rheumatoid arthritis. Rheumatology 45(7), 787-790 (2006).
72. Kamata Y, Nara H, Kamimura T et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern. Med. 43, 1201-1204 (2004).
73. Hagiwara K, Sato T, Takagi-Kobayashi S et al. Acute exacerbation of pre-existing interstitial lung disease after administration of etanercept for rheumatoid arthritis. J. Rheumatol. 34(5), 1151-1154 (2007).
74. Ostor AJK, Crisp AJ, Somerville MF, Scott DGI. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 27, 1266-1267 (2004).
75. Collins K, Todd A, Rynne M, Hamilton J, Saravanan V, Kelly CA. Re-adalimumab-associated pulmonary fibrosis. Rheumatology 46(8), 1379-1380 (2007).
76. Dixon W, Hyrich KL, Watson KD, Lunt M. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the BSR Biologics Register. Ann. Rheum. Dis. 69, 1086-1091 (2010). Important paper on the impact of anti-TNF on mortality in patients with RA-ILD.
77. Kelly C, Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother. 9, 3221-3230 (2008).
78. Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 49, 1354-1360 (2010).
79. Malik S, Toberty E, Thalayasingam N, Hamilton J, Kelly CA. Natural history of rheumatoid arthritis related interstitial lung disease. Rheumatology 51(3), iii 79 (2012).
80. Chapman J. Interstitial lung disease. www.clevelandclinicmeded.com/ medicalpubs/diseasemanagement